+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Herpes Marker Testing - Global Strategic Business Report

  • PDF Icon

    Report

  • 352 Pages
  • May 2026
  • Region: Global
  • Market Glass, Inc.
  • ID: 5140585
The global market for Herpes Marker Testing was estimated at US$527.0 Million in 2025 and is projected to reach US$731.1 Million by 2032, growing at a CAGR of 4.8% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Herpes Marker Testing Market - Key Trends and Drivers Summarized

Is Herpes Marker Testing the Key to Effective Management of Viral Infections?

Herpes marker testing plays a critical role in diagnosing and managing herpes simplex virus (HSV) infections, but why is this testing so essential? Herpes marker tests are used to detect the presence of antibodies or viral DNA in the body, helping clinicians identify whether an individual has been infected with HSV-1 or HSV-2, the two most common strains of the virus. HSV-1 is typically associated with oral herpes (cold sores), while HSV-2 is more commonly linked to genital herpes, although both types can infect either region. Herpes infections are widespread, with millions of people worldwide living with either type of the virus, many of whom are unaware they are carriers due to the often asymptomatic nature of the infection.

Herpes marker testing is critical for diagnosing the virus, particularly in asymptomatic individuals or those with mild symptoms, as they can unknowingly transmit the virus to others. Testing for herpes involves identifying specific antibodies (IgG or IgM) that the immune system produces in response to the infection or detecting viral DNA through polymerase chain reaction (PCR) tests. These tests help confirm whether someone has been exposed to the virus and, in many cases, can indicate whether the infection is recent or long-standing. Accurate diagnosis through herpes marker testing is essential for managing outbreaks, reducing the risk of transmission, and guiding treatment options to help individuals manage symptoms and prevent complications.

How Has Technology Advanced Herpes Marker Testing?

Technological advancements have significantly improved herpes marker testing, making it more accurate, faster, and accessible. One of the most significant innovations in this field is the development of polymerase chain reaction (PCR) testing, which allows for the direct detection of viral DNA. PCR testing is highly sensitive and can detect even small amounts of the virus in various sample types, such as blood, saliva, or lesion swabs. This method offers rapid and precise results, often within a few hours, making it one of the most reliable diagnostic tools for detecting active herpes infections. PCR tests have become the gold standard for diagnosing HSV infections, especially in cases where a definitive diagnosis is needed quickly, such as during an acute outbreak.

Serological testing, which identifies the presence of antibodies against HSV, has also improved. Traditional blood tests could sometimes struggle to differentiate between HSV-1 and HSV-2 infections. However, modern serological tests now offer type-specific antibody detection, allowing clinicians to distinguish between the two types of the virus. This distinction is crucial because HSV-1 and HSV-2 have different transmission patterns and recurrence rates, which can influence how a patient manages their infection. Type-specific IgG antibody tests can indicate whether someone has had a past infection, while IgM tests help identify recent or primary infections.

Additionally, point-of-care (POC) testing for herpes is becoming increasingly available. These rapid tests offer on-the-spot results, making them useful in urgent care or sexual health clinics where quick diagnosis is critical. Newer technologies are also exploring multiplex testing, which allows for the simultaneous detection of multiple sexually transmitted infections (STIs) alongside HSV, improving efficiency and reducing the number of tests needed to diagnose co-infections. These advancements in herpes marker testing not only improve diagnostic accuracy but also speed up the process, enabling earlier intervention and better management of herpes infections.

Why Is Herpes Marker Testing Critical for Public Health and Personal Management?

Herpes marker testing is vital for public health and personal management because it enables individuals and healthcare providers to detect and control the spread of herpes simplex virus infections, particularly when symptoms are mild or absent. Many people with herpes are unaware of their infection because it can remain dormant in the body for long periods, only causing outbreaks when triggered by factors like stress, illness, or a weakened immune system. Without proper testing, these individuals may unknowingly transmit the virus to others, contributing to its spread. Testing for herpes markers helps identify carriers and allows them to take precautions, such as using antiviral medications or practicing safer sexual behaviors, to reduce the risk of transmission.

For individuals, herpes marker testing provides clarity and peace of mind, particularly if they are experiencing unexplained symptoms like genital or oral sores, itching, or discomfort. A confirmed diagnosis allows healthcare providers to develop a tailored management plan, which may include antiviral medications like acyclovir, valacyclovir, or famciclovir to reduce the frequency and severity of outbreaks. Knowing their HSV status also empowers individuals to take preventive steps to avoid passing the virus to sexual partners, especially during asymptomatic shedding when the virus can still be transmitted.

In pregnant women, herpes marker testing is particularly critical. HSV infections, especially when acquired during pregnancy, can pose risks to the baby, leading to neonatal herpes, a serious condition that can cause permanent disability or death if not treated promptly. Identifying herpes infections early allows doctors to take preventive measures, such as prescribing antiviral medications in the late stages of pregnancy or recommending a cesarean delivery if there are active lesions during labor, to reduce the risk of transmitting the virus to the newborn.

On a larger scale, herpes marker testing is crucial for managing the overall public health impact of HSV infections. The virus is one of the most prevalent sexually transmitted infections globally, and widespread testing can help reduce its transmission rate by identifying and treating carriers. Early detection and effective management of herpes infections also help reduce the stigma associated with the virus, which can prevent individuals from seeking testing or treatment. By normalizing testing and offering easy access to diagnostics, public health systems can more effectively manage the spread of HSV, protect vulnerable populations, and improve the quality of life for those living with the virus.

What Factors Are Driving the Growth of the Herpes Marker Testing Market?

The growth of the herpes marker testing market is driven by several key factors, including rising awareness of sexually transmitted infections (STIs), advancements in testing technologies, and the increasing prevalence of herpes simplex virus infections globally. One of the primary drivers is the growing awareness of STIs and the importance of regular screening. Public health campaigns and educational programs are encouraging more people to get tested for herpes and other STIs, particularly as awareness increases about the asymptomatic nature of HSV infections. This shift in public health awareness is leading to higher demand for herpes marker testing in clinics, hospitals, and at-home testing kits.

Technological advancements in diagnostic testing are also contributing to the growth of the herpes marker testing market. The development of more accurate, faster, and cost-effective tests, such as PCR and multiplex testing, is making herpes diagnostics more accessible to healthcare providers and patients. These technologies allow for quicker turnaround times, which is especially important in managing acute outbreaks and preventing transmission. The introduction of point-of-care (POC) tests that deliver rapid results is another factor fueling market expansion, particularly in regions where healthcare infrastructure may be limited or where immediate results are necessary for treatment decisions.

The rising prevalence of herpes infections is another significant factor driving market growth. The World Health Organization (WHO) estimates that more than 3.7 billion people under the age of 50 have HSV-1, and over 490 million people aged 15-49 have HSV-2. As these infections remain widespread and incurable, the demand for effective diagnostic tools to manage and monitor herpes infections continues to grow. The increasing recognition of the health risks associated with undiagnosed or untreated herpes, such as complications during pregnancy and heightened risk of HIV transmission, is prompting more individuals to seek testing.

The growth of at-home testing options is another trend contributing to market expansion. With the rise of telemedicine and digital health platforms, at-home herpes testing kits are becoming more popular, providing a convenient, discreet, and accessible way for individuals to learn their HSV status. These kits allow users to collect a sample at home and send it to a laboratory for analysis, with results delivered confidentially via secure online platforms. The convenience and privacy offered by these services are encouraging more people, particularly younger and tech-savvy populations, to take charge of their sexual health and get tested.

Lastly, increasing healthcare initiatives and government programs aimed at reducing the prevalence of sexually transmitted infections are driving demand for herpes marker testing. Governments and global health organizations are investing in STI prevention and control programs, which include expanding access to diagnostic testing for herpes and other infections. These initiatives, combined with greater public awareness and technological advancements, are expected to drive steady growth in the herpes marker testing market in the coming years, ensuring that more individuals can access accurate diagnostics and effective care.

Report Scope

The report analyzes the Herpes Marker Testing market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:
  • Segments: Test Type (Antibody / Antigen-Based Kits, Nucleic Acid Amplification-Based Kits, Viral Culture Test); End-Use (Diagnostic Centers, Hospitals, Clinics, Academic & Research Institutes).
  • Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Viral Culture Test Kits Test segment, which is expected to reach US$305.4 Million by 2032 with a CAGR of 4.9%. The Nucleic Acid Amplification-based Kits Test segment is also set to grow at 5.6% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, valued at $163.0 Million in 2025, and China, forecasted to grow at an impressive 8.7% CAGR to reach $180.7 Million by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Herpes Marker Testing Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Herpes Marker Testing Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Herpes Marker Testing Market expected to evolve by 2032?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2032?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as B&B Manufacturing, Inc., Bedford Reinforced Plastics, Inc., Concrete Repairs Ltd., Creative Composites Group, Exel Composites Plc and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the companies featured in this Herpes Marker Testing market report include:

  • Abbott Laboratories
  • Abcam Ltd.
  • bioMerieux SA
  • Bio-Rad Laboratories, Inc.
  • DiaSorin SpA
  • F. Hoffmann-La Roche AG
  • Hologic, Inc.
  • Merck KgaA
  • Meridian Bioscience, Inc.
  • Norgen Biotek Corporation
  • Qiagen NV
  • QuidelOrtho Corporation
  • Teco Diagnostics
  • Thermo Fisher Scientific, Inc.

Domain Expert Insights

This market report incorporates insights from domain experts across enterprise, industry, academia, and government sectors. These insights are consolidated from multilingual multimedia sources, including text, voice, and image-based content, to provide comprehensive market intelligence and strategic perspectives. As part of this research study, the publisher tracks and analyzes insights from 2,587 domain experts. Clients may request access to the network of experts monitored for this report, along with the online expert insights tracker.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
  • Global Economic Update
  • Herpes Marker Testing - Global Key Competitors Percentage Market Share in 2026 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2026 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Global Prevalence of Herpes Infections Propels Demand for Herpes Marker Testing
  • Expansion of Diagnostic Testing in Sexual Health Clinics Fuels Market Growth
  • Role of Herpes Marker Testing in Reducing Transmission Rates and Enhancing Public Health Efforts
  • Expansion of Home-based and Self-testing Solutions Strengthens Business Case for Herpes Diagnostics
  • Growth in Digital Health Platforms for Telemedicine Consultations Expands Addressable Market
  • Challenges in Managing Social Stigma and Awareness of Herpes Infections Pose Barriers to Adoption
  • Expansion of Testing in Prenatal Care and High-risk Populations Drives Market Demand
  • Growth in Use of Multiplex Testing Panels for STDs Expands Market Opportunities
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Herpes Marker Testing Market Analysis of Annual Sales in US$ Thousand for Years 2020 through 2032
  • Table 2: World Recent Past, Current & Future Analysis for Herpes Marker Testing by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 3: World Historic Review for Herpes Marker Testing by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 4: World 13-Year Perspective for Herpes Marker Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets for Years 2020, 2026 & 2032
  • Table 5: World Recent Past, Current & Future Analysis for Viral Culture Test Kits Test by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 6: World Historic Review for Viral Culture Test Kits Test by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 7: World 13-Year Perspective for Viral Culture Test Kits Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 8: World Recent Past, Current & Future Analysis for Nucleic Acid Amplification-based Kits Test by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 9: World Historic Review for Nucleic Acid Amplification-based Kits Test by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 10: World 13-Year Perspective for Nucleic Acid Amplification-based Kits Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 11: World Recent Past, Current & Future Analysis for Antibody / Antigen-based Kits Test by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 12: World Historic Review for Antibody / Antigen-based Kits Test by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 13: World 13-Year Perspective for Antibody / Antigen-based Kits Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 14: World Recent Past, Current & Future Analysis for HSV-1 Indication by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 15: World Historic Review for HSV-1 Indication by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 16: World 13-Year Perspective for HSV-1 Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 17: World Recent Past, Current & Future Analysis for HSV-2 Indication by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 18: World Historic Review for HSV-2 Indication by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 19: World 13-Year Perspective for HSV-2 Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 20: World Recent Past, Current & Future Analysis for HSV-1 / HSV-2 Indication by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 21: World Historic Review for HSV-1 / HSV-2 Indication by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 22: World 13-Year Perspective for HSV-1 / HSV-2 Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 23: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 24: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 25: World 13-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 26: World Recent Past, Current & Future Analysis for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 27: World Historic Review for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 28: World 13-Year Perspective for Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 29: World Recent Past, Current & Future Analysis for Diagnostic Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 30: World Historic Review for Diagnostic Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 31: World 13-Year Perspective for Diagnostic Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 32: World Recent Past, Current & Future Analysis for Homecare Settings End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 33: World Historic Review for Homecare Settings End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 34: World 13-Year Perspective for Homecare Settings End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 35: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 36: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 37: World 13-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
III. MARKET ANALYSIS
UNITED STATES
  • Herpes Marker Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
CANADA
JAPAN
  • Herpes Marker Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
CHINA
  • Herpes Marker Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
EUROPE
  • Herpes Marker Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
FRANCE
  • Herpes Marker Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
GERMANY
  • Herpes Marker Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
ITALY
UNITED KINGDOM
  • Herpes Marker Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
SPAIN
RUSSIA
REST OF EUROPE
AUSTRALIA
  • Herpes Marker Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2026 (E)
INDIA
  • Herpes Marker Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2026 (E)
SOUTH KOREA
REST OF ASIA-PACIFIC
LATIN AMERICA
  • Herpes Marker Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2026 (E)
ARGENTINA
BRAZIL
MEXICO
REST OF LATIN AMERICA
MIDDLE EAST
  • Herpes Marker Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2026 (E)
IRAN
ISRAEL
SAUDI ARABIA
UNITED ARAB EMIRATES
REST OF MIDDLE EAST
AFRICA
  • Herpes Marker Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2026 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott Laboratories
  • Abcam Ltd.
  • bioMerieux SA
  • Bio-Rad Laboratories, Inc.
  • DiaSorin SpA
  • F. Hoffmann-La Roche AG
  • Hologic, Inc.
  • Merck KgaA
  • Meridian Bioscience, Inc.
  • Norgen Biotek Corporation
  • Qiagen NV
  • QuidelOrtho Corporation
  • Teco Diagnostics
  • Thermo Fisher Scientific, Inc.

Table Information